NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to prioritise exercise when taking them ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

A Fremont business owner was arrested on March 12 and charged with prescribing prescription drugs without a license and ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

Comedian Nikki Glaser defended those who are taking Ozempic for weight loss and wants people to feel more comfortable talking about it. Discussing the shame surrounding the weight-loss aid is “only ...